[1] Sahu P, Mudgal J, Arora D, et al. Cannabinoid receptor 2 activation mitigates lipopolysaccharide-induced neuroinflammation and sickness behavior in mice[J]. Psychopharmacology, 2019, 236(6): 1829-1838. [2] Carrera J, Tomberlin J, Kurtz J, et al. Endocannabinoid signaling for GABAergic-Microglia (Mis) Communication in the brain aging[J]. Front Neurosci, 2021, 14: 606808. [3] Hsieh GC, Pai M, Chandran P, et al. Central and peripheral sites of action for CB2 receptor mediated analgesic activity in chronic inflammatory and neuropathic pain models in rats[J]. Br J Pharmacol, 2011, 162(2): 428-440. [4] Komorowska-Müller JA, Schmöle AC. CB2 Receptor in Microglia: The guardian of Self-Control[J]. Int J Mol Sci, 2020, 22(1): 19. [5] Xin Q, Xu F, Taylor DH, et al. The impact of cannabinoid type 2 receptors (CB2Rs) in neuroprotection against neurological disorders[J]. Acta Pharmacol Sin, 2020, 41(12): 1507-1518. [6] Hsu SK, Li CY, Lin IL, et al. Inflammation-related pyroptosis, a novel programmed cell death pathway, and its crosstalk with immune therapy in cancer treatment[J]. Theranostics, 2021, 11(18): 8813-8835. [7] Shao BZ, Wei W, Ke P, et al. Activating cannabinoid receptor 2 alleviates pathogenesis of experimental autoimmune encephalomyelitis via activation of autophagy and inhibiting NLRP3 inflammasome[J]. CNS Neurosci Ther, 2014, 20(12): 1021-1028. [8] Kibret BG, Ishiguro H, Horiuchi Y, et al. New insights and potential therapeutic targeting of CB2 cannabinoid receptors in CNS disorders[J]. Int J Mol Sci, 2022, 23(2), 975. [9] Saghazadeh A, Ataeinia B, Keynejad K, et al. A meta-analysis of pro-inflammatory cytokines in autism spectrum disorders: Effects of age, gender, and latitude[J]. J Psychiatr Res, 2019, 115: 90-102. [10] Zou M, Liu Y, Xie S, et al. Alterations of the endocannabinoid system and its therapeutic potential in autism spectrum disorder[J]. Open Biol, 2021, 11(2): 200306. [11] Sánchez AJ, García-Merino A. Neuroprotective agents: Cannabinoids[J]. Clin Immunol, 2012, 142(1): 57-67. [12] Palazuelos J, Aguado T, Pazos MR, et al. Microglial CB2 cannabinoid receptors are neuroprotective in Huntington's disease excitotoxicity[J]. Brain, 2009, 132(11): 3152-3164. [13] Li J, Wang H, Liu D, et al. CB2R activation ameliorates late adolescent chronic alcohol exposure-induced anxiety-like behaviors during withdrawal by preventing morphological changes and suppressing NLRP3 inflammasome activation in prefrontal cortex microglia in mice[J]. Brain Behav Immun, 2023, 110: 60-79. [14] Çakir M, Tekin S, Doğanyiğit Z, et al. Cannabinoid type 2 receptor agonist JWH-133, attenuates Okadaic acid induced spatial memory impairment and neurodegeneration in rats[J]. Life Sci, 2019, 217: 25-33. [15] Zhang B, Zheng F, Liu A, et al. Activation of CB2 receptor inhibits pyroptosis and subsequently ameliorates cecal ligation and puncture-induced sepsis[J]. Int Immunopharmacol, 2021, 99: 108038. [16] Yamaori S, Ishii H, Chiba K, et al. Δ8-Tetrahydrocannabinol induces cytotoxicity in macrophage J774-1 cells: Involvement of cannabinoid receptor 2 and p38 MAPK[J]. Toxicology, 2013, 314(2-3): 254-261. [17] Hughes HK, Moreno RJ, Ashwood P. Innate immune dysfunction and neuroinflammation in autism spectrum disorder (ASD)[J]. Brain Behav Immun, 2023, 108: 245-254. [18] Mecha M, Feliú A, Carrillo-Salinas FJ, et al. Endocannabinoids drive the acquisition of an alternative phenotype in microglia[J]. Brain Behav Immun, 2015, 49: 233-245. [19] 张雪原,孔亚敏,马丙祥,等.孤独症谱系障碍动物模型相关神经生物学研究进展[J].中国实验动物学报,2022,30(8):1141-1149. Zhang XY, Kong YM, Ma BX, et al. Research progress in the neurobiology of animal models of autism spectrum disorder[J]. Acta Lab Anim Sci Sin, 2022, 30(8): 1141-1149.(in Chinese) [20] Arteaga-Henríquez G, Gisbert L, Ramos-Quiroga JA. Immunoregulatory and/or anti-inflammatory agents for the management of core and associated symptoms in individuals with autism spectrum disorder: A narrative review of randomized, placebo-controlled trials[J]. CNS Drugs, 2023, 37(3): 215-229. [21] Szabo A, O'connell KS, Akkouh IA, et al. Elevated levels of peripheral and central nervous system immune markers reflect innate immune dysregulation in autism spectrum disorder[J]. Psychiatry Res, 2024, 342: 116245. [22] Zhao P, Fu H, Cheng H, et al. Acupuncture at ST36 Alleviates the behavioral disorder of autistic rats by inhibiting TXNIP-mediated activation of NLRP3[J]. J Neuropathol Exp Neurol, 2022, 81(2): 127-134. [23] Komorowska-Müller JA, Ravichandran KA, Zimmer A, et al. Cannabinoid receptor 2 deletion influences social memory and synaptic architecture in the hippocampus[J]. Sci Rep, 2021, 11(1): 16828. [24] Komorowska-Müller JA, Rana T, Olabiyi BF, et al. Cannabinoid receptor 2 alters social memory and microglial activity in an age-dependent manner[J]. Molecules, 2021, 26(19): 5984. [25] Canseco-Alba A, Schanz N, Sanabria B, et al. Behavioral effects of psychostimulants in mutant mice with cell-type specific deletion of CB2 cannabinoid receptors in dopamine neurons[J]. Behav Brain Res, 2019, 360: 286-297. [26] Cortez IL, Silva NR, Rodrigues NS, et al. HU-910, a CB2 receptor agonist, reverses behavioral changes in pharmacological rodent models for schizophrenia[J]. Prog Neuro-Psychopharmacol Biol Psychiatry, 2022, 117: 110553. [27] Fyke W, Alarcon JM, Velinov M, et al. Pharmacological inhibition of the primary endocannabinoid producing enzyme, DGL-α, induces autism spectrum disorder-like and co-morbid phenotypes in adult C57BL/J mice[J]. Autism Res, 2021, 14(7): 1375-1389. |